Abstract: A pharmaceutical preparation is provided by a microcapsule containing a physiologically active substance which is water-soluble only at a pH of about 3 or below, and a polymer which is biodegradable upon oral administration. A process for producing the microcapsule is also provided.

Abstract: The present application relates to hair-care compositions comprising aqueous polymer dispersions as film-forming agent. These polymers are obtained by free-radical polymerization of a radical monomer in the interior and/or partially at the surface of already existing polymer particles of polyester type.

Abstract: The small particle liposome or lipid complex aerosol compounds and methods of treatment of the present invention involve lipid- or water soluble anti-cancer drugs incorporated into liposomes or other lipid complexes. The liposomes and complexes are administered in aqueous dispersions from a jet nebulizer to the respiratory tract of an individual. Various anti-cancer drugs may be used, including 20-S-Camptothecin, 9-Nitro-camptothecin, 9-Amino-camptothecin, 10, 11-methylenedioxy-camptothecin and taxol or its derivatives. Administration of these drugs by inhalation provides faster and more efficient absorption of the anticancer drug than does intramuscular administration or oral administration.

Abstract: The present invention discloses high viscosity sustained release dental compositions, such as tooth bleaching or fluoride compositions, for treating tooth surfaces. For maximum results, an improved dental tray having reservoirs for holding the dental composition adjacent the desired tooth surfaces is preferably used in combination with the sustained release dental composition. The sustained release dental compositions include a high carboxypolymethylene concentration which results in very high viscosity. The high level of carboxypolymethylene makes dilution of the dental compositions from saliva difficult and time consuming so that the compositions stay within the tray reservoirs, thereby providing sustained release. The concentrated carboxypolymethylene adds a unique tackiness to the dental composition which helps retain and seal the soft tray material against the patient's teeth.

Abstract: A pharmaceutical composition of water, water soluble vinyl polymer gel, amine alcohol dispersant and IEP is used topically to treat herpes labialis and aphthous stomatitis lesions, and also to treat herpes genitalis, chicken pox, allergic conjunctivitis, giant papillary conjunctivitis, stomatitis secondary to chemotherapy, thermal burn, sunburn, and decubitus ulcers and shingles.

Abstract: A skin care composition comprising an oil-in-water emulsion and a therapeutically effective amount of a retinoid selected from the group consisting of Vitamin A alcohol, Vitamin A aldehyde, retinyl acetate, retinyl palmitate and mixtures thereof, the composition having a pH of between about 4 and about 10 and further comprising an oil phase comprising one or more oils having a total unsaturation density, or C value, of about 1200 or less.

Abstract: An improved process for the treatment of human keratinous fibers, in particular hair, with a view especially to decreasing and/or preventing damage to the latter by bringing, for a period not exceeding 2 minutes, a gas containing steam and whose temperature is at least 75.degree. C., into contact with human keratinous fibers to which there has been applied a composition containing at least one amide compound which has at least one fatty chain with the exception of coprah diethanolamide and subsequently cooling the fibers thus treated. This process improves the binding of the amide on and/or in the hair, and results in an improvement in the cosmetic properties, in particular softness and smoothness.

Abstract: The present invention relates to hairspray compositions comprising from about 50% to about 99.9% by weight of an alcohol solvent, and from about 0.1% to about 30% by weight of a silicone-containing adhesive block copolymer having a weight average molecular weight from about 10,000 grams/mole to about 10,000,000 grams/mole and which is formed from the free radical polymerization of an ethylenically unsaturated monomer with select silicone macroinitiators, preferably silicone macroazoinitiators. The hairspray compositions, when dried, preferably have a cohesive strength of greater than about 0.5 kgf/mm.sup.2, a total energy absorption per unit volume of greater than about 0.55 kgfmm/mm.sup.3, an impact strength of greater than about 7000 ergs, and an improved removeability from hair as defined by a hair stiffness value of from 0 to about 3.5 (0 to 4 scale) and a hair flaking value of from 0 to about 3.5 (0 to 4 scale).

Abstract: Drug delivery to the pulmonary system has been achieved by encapsulation of the drug to be delivered in microparticles having a size range between 0.5 and ten microns, preferably in the range of two to five microns, formed of a material releasing drug at a pH of greater than 6.4. In a preferred embodiment, the drug delivery system is based on the formation of diketopiperazine microparticles which are stable at a pH of 6.4 or less and unstable at pH of greater than 6.4, or which are stable at both acidic and basic pH, but which are unstable at pH between about 6.4 and 8. Other types of materials can also be used, including biodegradable natural and synthetic polymers, such as proteins, polymers of mixed amino acids (proteinoids), alginate, and poly(hydroxy acids). In another embodiment, the microparticles have been modified to effect targeting to specific cell types and to effect release only after reaching the targeted cells.

Abstract: The invention relates to suspension aerosol formulations which exhibit stable particle sizes, containing mometasone furoate, about 1 to about 10 weight percent ethanol and 1,1,1,2,3,3,3-Heptafluoropropane as the propellant. A surfactant, such as oleic acid, can also be included. These formulations are suitable for use in metered dose inhalers.

Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increased rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HV-2) protease inhibitors are described.

Abstract: A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased duration of action.

Abstract: A method for alleviating the symptoms of an upper respiratory tract infection in humans employs the application of a composition containing, in a pharmaceutically acceptable carrier, 0.1 to 3.0 weight percent of a potassium salt such as one or more of potassium acetate, potassium aluminate, potassium arsenite solution, potassium bicarbonate, potassium bisulfate, potassium bitartarate, potassium bromide, potassium carbonate, potassium chloride, potassium citrate, potassium gluconate, potassium glycerophosphate, potassium iodate, potassium iodide, potassium manganate, potassium permanganate, potassium phosphate monobasic, potassium phosphate dibasic, potassium phosphate tribasic and potassium phosphite.

Abstract: In a method for treating lung diseases, a drug formulation is prepared by combining micronized crystalline beclomethasone dipropionate and lactose. The drug formulation is placed into a dry powder inhaler which provides inhalable drug particles having a mass median diameter of about 0.5-5.8 microns. The inhaler is preferably largely flow rate independent. Drug and lactose particles are separated in the inhaler during inhalation, most desirably via a spinning element. Due to deep deposition, the drug particles persist in the lungs for a surprisingly long duration, increasing the therapeutic effect of each dose. The patient inhales the drug particles with an inspiratory flow rate of about 10-60 liters/minute, to produce a deep lung deposition of inhaled particles.

Abstract: A method for the prophylactic and therapeutic treatment of bacterial infections is disclosed which comprises the treatment of an individual with an effective amount of a lytic enzyme composition specific for the infecting bacteria, with the lytic enzyme comprising an effective amount of lytic enzyme, wherein the lytic enzyme is in an environment having a pH which allows for activity of said lytic enzyme; and a carrier for delivering said lytic enzyme. This method, and composition can be used for the treatment of upper respiratory infections, skin infections, wounds, and burns, vaginal infections, eye infections, intestinal disorders and dental problems.

Abstract: The present invention discloses a method and composition for the topical treatment of streptococcal infections by the use of a lysin enzyme blended with a carrier suitable for topical application to dermal tissues. The method for the treatment of dermatological streptococcal infections comprises administering a composition comprising effective amount of a therapeutic agent, with the therapeutic agent comprising a lysin enzyme produced by group C streptococcal bacteria infected with a C1 bacteriophage. The therapeutic agent can be in a pharmaceutically acceptable carrier.

Abstract: A water-based composition for the treatment of hair or skin containing an active-substance combination of cosmetic components consisting of(a) an alkyl polyglycoside corresponding to general formula (I):RO--(Z).sub.x (I)in which R is an alkyl radical containing 6 to 22 carbon atoms, Z is a mono- or oligosaccharide and x is a number of 1.1 to 5, or adducts thereof with 1 to 10 moles of ethylene oxide or propylene oxide,(b) a polymer, and(c) a vegetable oil selected from kukui nut oil, almond oil, walnut oil, peach kernel oil, avocado oil, tea tree oil, soya oil, sesame oil, sunflower seed oil, tsubaki oil, evening primrose oil, rice bran oil, palm kernel oil, mango kernel oil, meadow foam oil, thistle oil, macadamia nut oil, grape seed oil, apricot kernel oil, babassu oil, olive oil, wheat germ oil, pumpkin seed oil, mallow oil, hazel nut oil, safflower oil, jojoba oil, canola oil, sasanqua oil and shea butter.

Abstract: Stabilized medicinal aerosol solution formulations comprising medicaments that degrade or decompose by interaction with solvents or water, an HFC propellant, a cosolvent and an acid are described. Further, specific medicinal aerosol solution formulations comprising ipratropium bromide or fenoterol, ethyl alcohol, 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, and either an inorganic acid or an organic acid are described. The acids are present in amounts sufficient to reduce the degradation of the medicaments to acceptable levels.

Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increase rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HIV-2) protease inhibitors are described.

Abstract: A medicinal aerosol formulation containing a particulate drug and a diol/diacid condensate as a dispersing aid.